Heberprot-P: A product that significantly favors the healing process of diabetic deep and complex ulcers and as result can reduce the risk of amputation.

At the CIGB •

• A novel and highly added value product (Heberprot-P) has been developed,
• Registry granted in Cuba since June 2006,
• Strong PCT patent application (granted so far in: Australia, China, Russia, Singapore and South Africa) of formulation and method of use,
• Pharmaceutical composition (human recombinant epidermal growth factor (EGFhrec) in an injectable formulation,
• Administered by local intralesional infiltration,
• Treatment of diabetic foot ulcer and reduction of risk of amputation ,